Ig Innovations Limited
Registered name: IG INNOVATIONS LIMITED
Part of Abbott Laboratories groupIg Innovations Limited made £67k revenue and a £599k loss in the year to 31 Dec 2024.
Ig Innovations Limited’s revenue fell 57% to £67k in the year to 31 Dec 2024, with a loss of £599k and 4 employees. The company is classified under “research and experimental development on biotechnology” and is based in Abingdon; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Abingdon, South East
- Age
- 16 yrs · since 2010
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £155k | £67k |
| Cost of sales | −£140k | −£118k |
| Gross profit | £15k | −£51k |
| Operating profit | −£273k | −£528k |
| Profit before tax | −£322k | −£599k |
| Profit (best available) | −£322k | −£599k |
| Employees (average) | 5 | 4 |
| Ratios | ||
| Profit margin | −207.7% | −894% |
| Gross margin | 9.7% | −76.1% |
| Revenue per employee | £31k | £16.8k |
| Profit per employee | −£64.4k | −£150k |
| Growth (year on year) | ||
| Revenue growth | — | ▼56.8% |
| Headcount growth | — | ▼20% |
| Balance sheet — indirect signals, not revenue | ||
| Net assets | — | — |
| Source | Accounts · bulk data Oct 2025 | Accounts · bulk data Oct 2025 |
How the business works
- Profit margin
- −894%
- Profit ÷ revenue.
- Gross margin
- −76.1%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £16.8k
- Revenue ÷ average employees.
- Profit per employee
- −£150k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- ▼20%
- Now 4
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- Abbott Laboratories (registered outside the UK register)ultimate parent75–100%
- Alere UK Holdings Limited75–100%
- Abbott Toxicology Limited75–100%
- Ig Innovations Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (3)
- Abbott Healthcare Connections LimitedRev. £7.8m · Profit £1m
- Forensics LimitedRev. £0 · Profit −£47k
- Cozart LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
Sources
Latest figures from accounts for the year to 31 Dec 2024 (profit −£599k), from the Companies House accounts bulk data published Oct 2025. Spotted an error? Request a correction.
Updated from Companies House on 12 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.